| Literature DB >> 33169204 |
Alexander F McDonald1,2,3, Yit Wooi Goh4, Jonathan M White3, Andrew M Scott1,2,5, Uwe Ackermann6,7,8.
Abstract
BACKGROUND: Oncrasin-1 is a small molecule which was identified from a screen of KRAS mutant cancer cells and has shown specificity for KRAS mutant cell killing. We aimed to develop a radiolabelled form of Oncrasin-1 to enable in-vivo imaging of mutant KRAS expression in malignant tumours. This work outlines the synthesis of 3 fluorinated derivatives and development of iodonium salt and boronic ester precursors for radiolabelling with the 18F isotope.Entities:
Keywords: 18F fluorination; Automated synthesis; Boronic ester; Iodonium salt; Oncology; Radiofluorination; Tracer development
Year: 2020 PMID: 33169204 PMCID: PMC7652984 DOI: 10.1186/s41181-020-00104-x
Source DB: PubMed Journal: EJNMMI Radiopharm Chem ISSN: 2365-421X
Fig. 1Parental compound, Oncrasin-1, and 3 fluorinated derivatives synthesized
Flexlab set up for radiolabelling reactions
| Container | Reagents |
|---|---|
| Vial 1 | Eluent |
| Vial 2 | 4 mg of precursor in 500 μl of DMF |
| Vial 3 | 1 ml anhydrous acetonitrile |
| Vial 4 | 450 μl of DMF. 50 μl of Pyridine, 15 mg of Cu(OTf)2 |
| Vial 5 | 1 ml of Acetonitrile and 1 ml of distilled water |
| Vial 6 | |
| Vial 7 | |
| Vial 8 | |
| Vial 9 | |
| Vial 10 | |
| Vial 11 | 10 ml of distilled water |
| Vial 12 | 1 ml of ethanol |
| Vial 13 | 1 ml of saline |
| Vial 14 | |
| Vial 15 | |
| Vial 16 | |
| Vial 17 | |
| Vial 18 | |
| Vial 19 | |
| QMA seppak | Quaternary Methyl Ammonium Cartridge |
| Seppak A | |
| Seppak B | |
| Seppak C | |
| Seppak D | C18 seppak |
| HPLC Vial 1 | |
| HPLC Vial 2 | 40 ml of distilled water |
| Reactor 1 | 1 ml anhydrous acetonitrile |
| Reactor 2 | |
| Loop Vial 1 | |
| Loop Vial 2 | 1 ml distilled water |
| HPLC eluent A | 0.1% Ammonium formate |
| HPLC eluent B | Acetonitrile |
| HPLC eluent C | Water |
| HPLC eluent D | Ethanol |
Fig. 2Flexlab module (left) and interactive control interface (right)
Scheme 1Standard coupling conditions for indole-3-carbaldehyde and various benzyl bromides
Scheme 2Proposed synthetic route for iodonium salt synthesis and subsequent labelling
Scheme 3Attempted initial iodonium salt synthesis
Reaction conditions trialled with for iodonium salt synthesis
| Oxidant | Counter ion | Aryl System |
|---|---|---|
| MCPBA | OTf/OTs | |
| Peroxide | OTs | 1,3, Dimethoxy Benzene |
| Oxone | OTs | 1,3,5 Trimethoxy Benzene |
| Sodium Periodate (Kazmierczak et al. | Acetic acid/H2SO4 | 1,3,5 Trimethoxy Benzene |
Scheme 4A 2-step approach to iodonium salt synthesis
Fig. 3Crystal structure and chemical drawing of a major product Step 1 in Scheme 4
Scheme 5Synthesis of boronic ester precursors via two routes
Scheme 6Initial radiolabelling trial conditions utilizing Treadwell conditions
Scheme 7Radiolabelling conditions used for labelling of model system
Trialled reaction conditions for model systems
| Reaction | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| Eluent | Carbonate | Tetrabutylamine | Bicarbonate | Triflate | |
| Catalyst | Tetrakis Complex | Tetrakis Complex | Tetrakis Complex | Cu(OTf)2 + Pyridine | Cu(OTf)2 + Pyridine |
| Kryptofix | 10 mg | – | 4.5 mg | 4.5 mg | |
| Outcome | Nil | Nil | Nil | Minor Product | Product |
Scheme 8Radiolabelling conditions for KAM001
Fig. 418F KAM001 identity confirmation using cold standard retention
Fig. 518F KAM002 identity confirmation using cold standard retention
Fig. 618F KAM003 identity confirmation using cold standard retention